Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Frequently asked questions
What sector does Krystal Biotech, Inc (KRYS) operate in?
Krystal Biotech, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Krystal Biotech, Inc (KRYS) current stock price?
As of the latest data, Krystal Biotech, Inc stock price is $328.34, with a previous close of $332.86. Krystal Biotech, Inc lost -$4.52 in the last trading session, representing a -1.36% loss.
What is Krystal Biotech, Inc (KRYS) current market capitalization?
Krystal Biotech, Inc market cap is approximately 9.72 billion.
What is Krystal Biotech, Inc (KRYS) Earnings Per Share (EPS)?
The trailing EPS is $7.76, and the forward EPS is $9.53.
What is Krystal Biotech, Inc (KRYS) Price-to-Earnings (P/E) ratio?
Krystal Biotech, Inc current P/E ratio is 42.31, with a forward P/E of 34.45.
What is Krystal Biotech, Inc (KRYS) EBITDA?
Krystal Biotech, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 66.08 million.
Does Krystal Biotech, Inc (KRYS) pay dividends?
No. Krystal Biotech, Inc does not pay a dividend.
How did Krystal Biotech, Inc (KRYS) perform in its most recent earnings report?
In the last report (June 30, 2026), Krystal Biotech, Inc posted an EPS surprise of 5.29% and a revenue surprise of -1.5%.
What is Krystal Biotech, Inc (KRYS) beta (volatility) score?
Krystal Biotech, Inc has a beta of 0.536, indicating lower volatility than the overall market.
